LOGIN  |  REGISTER
Chimerix

Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

September 27, 2023 | Last Trade: US$0.65 0.05 8.15

REDWOOD CITY, Calif. & BOSTON / Sep 27, 2023 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held in San Diego, CA from November 1-5, 2023.

Details of the poster presentation are as follows:

Abstract Title: Assay Development and Quantitative Detection of ADI-001, a CD20-Targeted γδ1 CAR T Therapy, using AlloCell, a Universal Assay for Monitoring of “Off-the-Shelf" Allogeneic Cell Therapies
Poster/Abstract Number: 684
Presenting Authors: Jackie Wilde, MS & Monica Moreno, PhD
Date/Time: November 4, 2023, from 9:00 a.m. - 8:30 p.m. PDT

Abstract Title: ADI-925: An Allogeneic “Off-the-Shelf" Chimeric Adapter (CAd) γδ T Cell Therapy Targeting NKG2D Ligand-Expressing Cancers
Poster/Abstract Number: 265
Presenting Authors: Marissa Herrman, PhD
Date/Time: November 3, 2023, from 9:00 a.m. - 8:30 p.m. PDT

Abstract Title: Disruption of the Cytokine Signaling Checkpoint CIS Enhances Serial-Killing and Anti-Tumor Activity of CAR-Engineered γδ T Cells
Poster/Abstract Number: 246
Presenting Authors: Beibei Ding, PhD
Date/Time: November 4, 2023, from 9:00 a.m. - 8:30 p.m. PDT

These abstracts will be available as a supplement in the Journal for ImmunoTherapy of Cancer (JITC) on Tuesday, October 31, 2023 at 9:00 a.m. EDT on www.sitcancer.org.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Chimerix

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page